Gapping up
In reaction to strong earnings/guidance:
- SBH +14.7% (Q3 revs outlook), HIMX +2.9%
Select Chinese ADRs showing strength after Shanghai closes 5.7% higher:
- NIO +21.9%, ASHR +9.1%, FXI +7.3%, WB +5.3%, JD +3.9%, BIDU +3.8%, BABA +3.8%
Other news:
- MESO +9.1% (initiates expanded access protocol for compassionate use of Remestemcel-L in children with multisystem inflammatory syndrome associated with COVID-19)
- DTIL +6.9% (notified by Gilead (GILD) of its termination of the Collaboration and License Agreement)
- UBER +6.4% (Bloomberg on Sunday said that UBER was buying Postmates for $2.65 bln in an all-stock transaction)
- SEAS +4.6% (files for $500 mln mixed securities shelf offering)
- BDX +4.1% (launches portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutes, dramatically expanding access to COVID-19 Testing)
- MYGN +3.7% (announced new collaboration with OptraHEALTH to implement a cognitive ChatBOT named Gene to provide genetic and financial assistance information to prospective patients)
- MYL +3.3% (secures regulatory approval for remdesivir lyophilized powder for injection 100 mg/vial in India for Restricted Emergency Use in COVID-19 patients)
- DOW +3.1% (announces sale of rail infrastructure assets at six North American sites)
- REGN +2.9% (starts REGN-COV2 Phase 3 COVID-19 prevention trial)
- RRR +2.4% (reports the death of its President Richard Haskins )
- CVM +1.9% (confirms filing for 613,792 share common stock offering by selling shareholders)
- APT +1.8% (Texas governor mandates masks)
- GILD +1.8% (receives conditional Marketing Authorization for Veklury (remdesivir) for the Treatment of COVID-19)
- HTGC +1.7% (files for 16.5 mln share common stock offering)
- ABT +1.4% (receives FDA approval for Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices)
- EBS +1.1% (signs five-year agreement for large-scale drug substance manufacturing for Johnson & Johnson's lead COVID-19 vaccine candidate; first two years valued at $480 mln)
Analyst comments:
- TSLA +5.5% (target raised to $1500 from $1050 at JMP Securities)
- CYBR +2% (upgraded to Buy at Monness Crespi & Hardt)
- CCEP +1.7% (upgraded to Buy from Hold at ABN Amro)